[HTML][HTML] Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - BMC medicine, 2023 - Springer
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin… - BMC …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin… - BMC …, 2023 - search.proquest.com
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - BMC Medicine, 2023 - go.gale.com
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
[PDF][PDF] Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - 2023 - d-nb.info
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
[HTML][HTML] Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor …
W Zhao, A Song, Y Xu, Q Wu, C Liu… - BMC …, 2023 - bmcmedicine.biomedcentral.com
Compound epidermal growth factor receptor (EGFR) mutations are less responsive to
tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell lung cancer …
tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell lung cancer …
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin… - BMC …, 2023 - search.ebscohost.com
Background: Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - BMC Medicine, 2023 - europepmc.org
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
[HTML][HTML] Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - BMC …, 2023 - ncbi.nlm.nih.gov
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
[PDF][PDF] Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor …
W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - 2023 - bmcmedicine.biomedcentral.com
Background Compound epidermal growth factor receptor (EGFR) mutations are less
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …
responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell …